Search results for "From ACP Journal Club"
Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of age
The U.S. Preventive Services Task Force (USPSTF) issued a recommendation on use of statins for primary prevention of cardiovascular disease (CVD).
https://diabetes.acponline.org/archives/2017/04/14/6.htm
14 Apr 2017
Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes
Having diabetes was associated with higher risk of a major cardiovascular event after implementation of a drug-eluting stent, according to a systematic review.
https://diabetes.acponline.org/archives/2017/03/10/6.htm
10 Mar 2017
Semaglutide reduced a composite of CV events at two years in patients with type 2 diabetes and high CV risk
Semaglutide, a new once-weekly glucagon-like peptide-1 (GLP-1) analogue, reduced cardiovascular (CV) events compared to placebo, according to a manufacturer-sponsored study.
https://diabetes.acponline.org/archives/2017/02/10/7.htm
10 Feb 2017
Review: In type 2 diabetes, sodium–glucose cotransporter 2 inhibitors do not increase major CV events or mortality
The meta-analysis included 37 trials that compared canagliflozin, dapagliflozin, or empagliflozin to placebo or other active antidiabetic treatments.
https://diabetes.acponline.org/archives/2017/02/10/6.htm
10 Feb 2017
In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis
The study authors concluded that the negative effects observed would limit clinical use of liraglutide in patients with type 1 diabetes.
https://diabetes.acponline.org/archives/2017/01/13/6.htm
13 Jan 2017
Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo
A review published prior to the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes trial found that aspirin only reduced cardiovascular events in diabetes patients with pre-existing cardiovascular disease.
https://diabetes.acponline.org/archives/2016/12/09/5.htm
9 Dec 2016
In type 2 diabetes treated with high-dose insulin, liraglutide reduced HbA1c
The hypoglycemia rate was higher in the first month after initiation of liraglutide, but the overall hypoglycemia rate over the 6-month follow-up was similar in liraglutide and placebo patients.
https://diabetes.acponline.org/archives/2016/11/11/5.htm
11 Nov 2016
In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y
A subanalysis of a trial of empagliflozin for patients with cardiovascular disease (CVD) found lower rates of nephropathy in those randomized to empagliflozin rather than placebo.
https://diabetes.acponline.org/archives/2016/11/11/7.htm
11 Nov 2016
In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y
The study's primary composite outcome was first occurrence of death from cardiovascular (CV) causes, nonfatal (including silent) myocardial infarction, or nonfatal stroke.
https://diabetes.acponline.org/archives/2016/11/11/6.htm
11 Nov 2016
Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients
More than 20% of patients with type 2 diabetes received treatment more intensive than that recommended by HbA1c-based guidelines, a study of Medicare patients found.
https://diabetes.acponline.org/archives/2016/10/07/5.htm
7 Oct 2016